NYSE:NNVC NanoViricides (NNVC) Stock Price, News & Analysis $1.39 -0.03 (-1.77%) Closing price 08/29/2025 03:59 PM EasternExtended Trading$1.41 +0.02 (+1.44%) As of 08/29/2025 06:16 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsEarningsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About NanoViricides Stock (NYSE:NNVC) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get NanoViricides alerts:Sign Up Key Stats Today's Range$1.37▼$1.4250-Day Range$1.23▼$1.7552-Week Range$0.94▼$2.02Volume109,378 shsAverage Volume238,649 shsMarket Capitalization$22.34 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview NanoViricides, Inc., a clinical stage nano-biopharmaceutical company, discovers, develops, and commercializes drugs for the treatment of viral infections. The company's product portfolio includes NV-CoV-2, nanoviricide drug which is in phase 1a/1b clinical trails for the treatment of Covid; and NV-CoV-2 Oral Syrup, and NV-CoV-2 Oral Gummies, a semi-solid fixed-dose form which are in phase 1a/1b human clinical trials for enabling body-weight-based dose titration as is required for pediatric cases. It also offers NV-CoV-2 Solution for injection, infusion, and inhalation to treat severe cases that are not yet hospitalized would be best performed by an injection; and injectable solution can be delivered directly into the lungs as a fog created using standard portable battery operated nebulizer devices which enables action at the most important site of infection by a respiratory virus, such as coronaviruses, RSV, influenzas, human meta-pneumovirus, certain adenoviruses, and other infections, that can lead to severe pneumonia. In addition, the company provides Nanoviricide, a biomimetic platform technology designed to attack enveloped virus particles to deliver anti-viral payload into infected cells sparing uninfected cells to block replication cycle without toxicity. NanoViricides, Inc. was incorporated in 2005 and is headquartered in Shelton, Connecticut. Read More NanoViricides Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks8th Percentile Overall ScoreNNVC MarketRank™: NanoViricides scored higher than 8% of companies evaluated by MarketBeat, and ranked 920th out of 944 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for NanoViricides. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of NanoViricides is -1.93, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of NanoViricides is -1.93, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioNanoViricides has a P/B Ratio of 2.11. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.57% of the float of NanoViricides has been sold short.Short Interest Ratio / Days to CoverNanoViricides has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in NanoViricides has recently decreased by 19.91%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldNanoViricides does not currently pay a dividend.Dividend GrowthNanoViricides does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted0.57% of the float of NanoViricides has been sold short.Short Interest Ratio / Days to CoverNanoViricides has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in NanoViricides has recently decreased by 19.91%, indicating that investor sentiment is improving significantly. News and Social Media1.5 / 5News Sentiment-0.28 News SentimentNanoViricides has a news sentiment score of -0.28. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 1.05 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for NanoViricides this week, compared to 1 article on an average week.Search InterestOnly 3 people have searched for NNVC on MarketBeat in the last 30 days. This is a decrease of -25% compared to the previous 30 days.MarketBeat Follows14 people have added NanoViricides to their MarketBeat watchlist in the last 30 days. This is an increase of 367% compared to the previous 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, NanoViricides insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.60% of the stock of NanoViricides is held by insiders.Percentage Held by InstitutionsOnly 10.30% of the stock of NanoViricides is held by institutions.Read more about NanoViricides' insider trading history. Receive NNVC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for NanoViricides and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. NNVC Stock News HeadlinesNanoViricides Reports NV-387’s Anti-Inflammatory Effects Could Combat Viral-Induced Cancer ResurgenceAugust 27 at 8:49 AM | theglobeandmail.comNanoViricides says broad-spectrum antiviral candidate NV-387 could address current, emerging and future COVID strainsAugust 27 at 8:47 AM | proactiveinvestors.comBuffett to put 90% of his money in this one stock?CPA and CFA says you have WAY too many stocks - just buy these 3 After years working at the biggest accounting firms like Deloitte and KPMG, Joel Litman (who’s also a member of the Global CFA Institute) figured out a unique, less-risky way to grow rich in the stock market. Litman says you don’t need dozens of investments, overpriced advisers, or hedge funds. You just need these 3 stocks, which have helped Litman’s own mom earn 3,400%.August 30 at 2:00 AM | Altimetry (Ad)NanoViricides says antiviral NV-387 may reduce cancer resurgence risk tied to viral infectionsAugust 18, 2025 | proactiveinvestors.comNanoViricides says antiviral candidate NV-387 could address global measles surgeJuly 30, 2025 | proactiveinvestors.comNanoViricides eyes revenue opportunities with broad-spectrum antiviral NV-387July 23, 2025 | proactiveinvestors.comMeasles Now Has a Drug – NV-387 Broad-Spectrum Antiviral Successful in Animal Studies, says NanoViricidesJuly 21, 2025 | usatoday.comNanoViricides says lead antiviral boosted survival in measles-infected miceJuly 21, 2025 | proactiveinvestors.comSee More Headlines NNVC Stock Analysis - Frequently Asked Questions How have NNVC shares performed this year? NanoViricides' stock was trading at $1.43 on January 1st, 2025. Since then, NNVC stock has decreased by 2.8% and is now trading at $1.39. How were NanoViricides' earnings last quarter? NanoViricides, Inc. (NYSE:NNVC) issued its earnings results on Friday, September, 27th. The company reported ($0.19) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.20) by $0.01. When did NanoViricides' stock split? NanoViricides shares reverse split on the morning of Tuesday, September 24th 2019.The 1-20 reverse split was announced on Thursday, September 12th 2019. The number of shares owned by shareholders was adjusted after the market closes on Monday, September 23rd 2019. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. Who are NanoViricides' major shareholders? NanoViricides' top institutional investors include XTX Topco Ltd (0.13%). View institutional ownership trends. How do I buy shares of NanoViricides? Shares of NNVC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of NanoViricides own? Based on aggregate information from My MarketBeat watchlists, some other companies that NanoViricides investors own include Cytosorbents (CTSO), Rekor Systems (REKR), NVIDIA (NVDA), Micron Technology (MU), Inovio Pharmaceuticals (INO), Meta Platforms (META) and Advanced Micro Devices (AMD). Company Calendar Last Earnings9/27/2024Today8/30/2025Fiscal Year End6/30/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNYSE:NNVC CIK1379006 Webwww.nanoviricides.com Phone(203) 937-6137Fax203-859-5095Employees20Year FoundedN/AProfitability EPS (Trailing Twelve Months)($0.70) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$8.29 million Net MarginsN/A Pretax MarginN/A Return on Equity-87.90% Return on Assets-78.69% Debt Debt-to-Equity RatioN/A Current Ratio3.44 Quick Ratio2.47 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.66 per share Price / Book2.11Miscellaneous Outstanding Shares16,072,000Free Float14,922,000Market Cap$22.34 million OptionableOptionable Beta0.96 Social Links 10 Best Stocks to Own: Fall 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free Report This page (NYSE:NNVC) was last updated on 8/30/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredMy NEXT $1 Trillion PredictionJames Altucher is making his next trillion-dollar prediction — and this time, it’s not Apple. He believes Elon...Paradigm Press | SponsoredTrump’s national nightmare is hereAI is no longer just about chatbots — it’s becoming the backbone of the global economy. While U.S. firms push ...Porter & Company | Sponsored“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NanoViricides, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share NanoViricides With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.